Evidence map›Paper›PMID 33799689›Full record

ArticleMolecules (Basel, Switzerland)2021

Chrysin Derivative CM1 and Exhibited Anti-Inflammatory Action by Upregulating Toll-Interacting Protein Expression in Lipopolysaccharide-Stimulated RAW264.7 Macrophage Cells.

Eui-Baek Byun, Ha-Yeon Song, Woo Sik Kim, Jeong Moo Han, Ho Seong Seo, Woo Yong Park, Kwangwook Kim, Eui-Hong Byun

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eui-Baek ByunAdvanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup 56212, Korea.
Ha-Yeon SongAdvanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup 56212, Korea.
Woo Sik KimFunctional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup 56212, Korea.
Jeong Moo HanAdvanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup 56212, Korea.
Ho Seong SeoAdvanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup 56212, Korea.
Woo Yong ParkDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea.
Kwangwook KimDepartment of Food Science and Technology, Kongju National University, Yesan 32439, Korea.
Eui-Hong ByunDepartment of Food Science and Technology, Kongju National University, Yesan 32439, Korea.
Korea Atomic Energy Research Institute · KRKongju National University · KR

Funding

National Research Foundation of Korea NRF-2019R1C1C1002484Nuclear R&D Program of Ministry of Science and ICT No grant number.
6 · The paper itself

Abstract

Although our previous study revealed that gamma-irradiated chrysin enhanced anti-inflammatory activity compared to intact chrysin, it remains unclear whether the chrysin derivative, CM1, produced by gamma irradiation, negatively regulates toll-like receptor (TLR) signaling. In this study, we investigated the molecular basis for the downregulation of TLR4 signal transduction by CM1 in macrophages. We initially determined the appropriate concentration of CM1 and found no cellular toxicity below 2 μg/mL. Upon stimulation with lipopolysaccharide (LPS), CM1 modulated LPS-stimulated inflammatory action by suppressing the release of proinflammatory mediators (cytokines TNF-α and IL-6) and nitric oxide (NO) and downregulated the mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signaling pathways. Furthermore, CM1 markedly elevated the expression of the TLR negative regulator toll-interacting protein (Tollip) in dose- and time-dependent manners. LPS-induced expression of cell surface molecules (CD80, CD86, and MHC class I/II), proinflammatory cytokines (TNF-α and IL-6), COX-2, and iNOS-mediated NO were inhibited by CM1; these effects were prevented by the knockdown of Tollip expression. Additionally, CM1 did not affect the downregulation of LPS-induced expression of MAPKs and NF-κB signaling in Tollip-downregulated cells. These findings provide insight into effective therapeutic intervention of inflammatory disease by increasing the understanding of the negative regulation of TLR signaling induced by CM1.

Indexed as

AnimalsAnti-Inflammatory AgentsFlavonoidsInflammationInterleukin-6Intracellular Signaling Peptides and ProteinsLipopolysaccharidesMacrophagesMiceMitogen-Activated Protein KinasesNF-kappa BNitric OxideRAW 264.7 CellsSignal TransductionToll-Like Receptor 4Toll-Like ReceptorsAnti-Inflammatory AgentschrysinFlavonoidsInterleukin-6Intracellular Signaling Peptides and ProteinsLipopolysaccharidesMitogen-Activated Protein KinasesNF-kappa BNitric OxideTlr4 protein, mouseTollip protein, mouseToll-Like Receptor 4Toll-Like ReceptorsTumor Necrosis Factor-alphaanti-inflammatory activitychrysin derivativemacrophagetoll-interacting proteintoll-like receptor negative regulator

Identifiers

PMID33799689
PMCPMC8000858
OpenAlexW3134354968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.